Interactions with the FDA
A priority for the REiNS International Collaboration is to develop and maintain a working relationship with members of the Federal Drug Administration (FDA) as an important stakeholder in neurofibromatosis clinical trial outcomes and study design. FDA representatives attend our two yearly meetings and present on topics relevant to our work, and REiNS members have presented about our group initiatives at two meetings at the FDA. These continued interactions are critical to both the REiNS group and the FDA for making progress in the development of clinical trials and approval of new treatments for NF1, NF2, and schwannomatosis.
Specific Topic Meetings
| Meeting Type | Meeting Date/Agenda | Presentation | ||||
| Critical Path Innovation Meeting | 2/5/2021 | Embedding Qualitative Patient Interviews in Neurofibromatosis Clinical Trials to Facilitate Drug Development | ||||
Specific Information from the FDA/EMA
FDA and EMA drug development links
Overview
Content Tools
ThemeBuilder